Medical/Pharmaceuticals
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft
tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the
appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr
as a Non-Executive Director to the board.
2022-09-14 13:05
3436
Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false. It is understood that Fosun h...
2022-09-14 12:11
3897
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD
Anderson Cancer Center
2022-09-14 11:09
1940
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s,among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS wa...
2022-09-14 09:11
2850
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022
* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line（1L）treatment for advanced NSCLC patients * In 87 efficacy evaluable patients, confirmed ORR was 46%. * Median OS in non-squ...
2022-09-14 09:04
2720
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence
SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...
2022-09-14 08:30
5360
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investm...
2022-09-14 00:48
2197
New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open
* Joint study with Massachusetts General Hospital proves that Lunit's
AI-powered chest x-ray analysis software enhances the overall performance and
efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A
recent study published in
2022-09-13 22:16
2141
TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism
BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ -- Concept Medical
2022-09-13 22:15
3411
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announ...
2022-09-13 22:00
3342
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"
* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...
2022-09-13 21:00
2274
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...
2022-09-13 20:38
3336
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...
2022-09-13 20:00
2824
AO Foundation acquires RIMASYS to advance the surgical education ecosystem of the future
DAVOS, Switzerland and COLOGNE, Germany, Sept. 13, 2022 /PRNewswire/ -- The AO
Foundation and RIMASYS are pleased to announce that they have taken their
strategic partnership to the next level with a full-stake investment by the AO
in RIMASYS.
2022-09-13 18:00
2771
TikoMed's ILB(R) inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candid...
2022-09-13 16:08
2338
SmartFuture's White-label Remote Patient Monitoring Platform goes global
SINGAPORE, Sept. 13, 2022 /PRNewswire/ -- SmartFuture's white-label Remote Patient Monitoring (RPM) platform is now being deployed successfully in 11 countries, includingSingapore, Malaysia, other ASEAN countries, India and most recently, inthe United States. According to Sumit Khemani, CEO, "...
2022-09-13 16:03
4555
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO
HONG KONG, Sept, 13, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, published encouraging preclinical results in poster featuring its F...
2022-09-13 14:02
1964
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be presented at the34th Transcatheter Cardiovascular Therapeutics (TCT), the annua...
2022-09-13 09:11
2550
CStone announces China's NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* This is the third supplemental new drug application (NDA) that CStone has submitted for sugemalimab after the prior two for stage III and IV non-small cell lung cancer. Sugemalimab has the potential to become the world's first immuno-oncology therapy to be approved for patients with relapsed ...
2022-09-13 08:02
5460
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
* In first line treatment of advanced or metastatic G/GEJ cancer, early interim data of the first 15 patients with measurable disease receiving the combination of TST001 (Osemitamab) with CAPOX demonstrated a partial response rate of 73.3% and a disease control rate of 100% per RECIST1.1. * B...
2022-09-13 08:00
3653
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52884
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51703
